Sun Pharma Receives FDA Warning for Dadra Facility

Sun Pharmaceutical Industries Ltd. received a warning letter from the US Food and Drug Administration (FDA) for its Dadra facility, citing violations of Current Good Manufacturing Practice (cGMP) regulations. This development adversely affected Sun Pharma's stock, which dropped nearly 2% to Rs 1,475 on June 20, following a previous day's decline. The stock underperformed against the Nifty 50 index, which saw a 0.15% decrease on June 19.

Earlier in April, the FDA had issued an Official Action Indicated (OAI) status after inspecting the Dadra unit in December 2023. This designation implies potential regulatory or administrative actions against the company or its facilities.During Sun Pharma's recent earnings call with analysts, Chairman and Managing Director Dilip Shanghvi expressed concern over the audit outcomes and emphasized the company's commitment to addressing the findings to improve performance in future audits.The Dadra facility plays a crucial role in manufacturing oral solid dosage forms and generic Revlimid, a significant revenue driver for several pharmaceutical companies, including Dr. Reddy's.